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Abstract
Congenital hypothyroidism (CH) occurs in approximately 1:2,000 to 1:4,000 newborns. The clinical manifestations
are often subtle or not present at birth. This likely is due to trans-placental passage of some maternal thyroid hor-
mone, while many infants have some thyroid production of their own. Common symptoms include decreased
activity and increased sleep, feeding difficulty, constipation, and prolonged jaundice. On examination, common
signs include myxedematous facies, large fontanels, macroglossia, a distended abdomen with umbilical hernia, and
hypotonia. CH is classified into permanent and transient forms, which in turn can be divided into primary, second-
ary, or peripheral etiologies. Thyroid dysgenesis accounts for 85% of permanent, primary CH, while inborn errors of
thyroid hormone biosynthesis (dyshormonogeneses) account for 10-15% of cases. Secondary or central CH may
occur with isolated TSH deficiency, but more commonly it is associated with congenital hypopitiutarism. Transient
CH most commonly occurs in preterm infants born in areas of endemic iodine deficiency. In countries with new-
born screening programs in place, infants with CH are diagnosed after detection by screening tests. The diagnosis
should be confirmed by finding an elevated serum TSH and low T4 or free T4 level. Other diagnostic tests, such as
thyroid radionuclide uptake and scan, thyroid sonography, or serum thyroglobulin determination may help pin-
point the underlying etiology, although treatment may be started without these tests. Levothyroxine is the treat-
ment of choice; the recommended starting dose is 10 to 15 mcg/kg/day. The immediate goals of treatment are to
rapidly raise the serum T4 above 130 nmol/L (10 ug/dL) and normalize serum TSH levels. Frequent laboratory mon-
itoring in infancy is essential to ensure optimal neurocognitive outcome. Serum TSH and free T4 should be mea-
sured every 1-2 months in the first 6 months of life and every 3-4 months thereafter. In general, the prognosis of
infants detected by screening and started on treatment early is excellent, with IQs similar to sibling or classmate
controls. Studies show that a lower neurocognitive outcome may occur in those infants started at a later age (> 30
days of age), on lower l-thyroxine doses than currently recommended, and in those infants with more severe
hypothyroidism.
Definition and classification
Congenital hypothyroidism (CH) is defined as thyroid
hormone deficiency present at birth. Thyroid hormone
deficiency at birth is most commonly caused by a pro-
blem with thyroid gland development (dysgenesis) or a
disorder of thyroid hormone biosynthesis (dyshormono-
genesis). These disorders result in primary hypothyroid-
ism. Secondary or central hypothyroidism at birth
results from a deficiency of thyroid stimulating hormone
(TSH). Congenital TSH deficiency may rarely be an iso-
lated problem (caused by mutations in the TSH b subu-
nit gene), but most commonly it is associated with other
pituitary hormone deficiencies, as part of congenital
hypopituitarism. Peripheral hypothyroidism is a separate
category resulting from defects of thyroid hormone
transport, metabolism, or action.
Congenital hypothyroidism is classified into permanent
and transient CH. Permanent CH refers to a persistent
deficiency of thyroid hormone that requires life-long treat-
ment. Transient CH refers to a temporary deficiency of
thyroid hormone, discovered at birth, but then recovering
to normal thyroid hormone production. Recovery to
euthyroidism typically occurs in the first few months or
years of life. Permanent CH can be further classified into
permanent primary and secondary (or central) CH; transi-
ent primary CH has also been reported. In addition, some
forms of CH are associated with defects in other organ
systems; these are classified as syndromic hypothyroidism.
The underlying etiology of CH typically will determine
whether hypothyroidism is permanent or transient,
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involvement of other organ systems (see section on
Etiology for details). The primary emphasis of this
review is a discussion of primary CH, but there also will
be some discussion of secondary or central CH. It
should be borne in mind that an underlying etiology
may not be determined for many cases of CH. Further,
while the exact cause of some cases of thyroid dysgen-
esis is known, e.g., a mutation in the TTF-2 gene, muta-
tions in genes encoding such transcription factors
important in thyroid gland development have been
found in only 2% of cases. Thus, an exact cause for the
vast majority of cases of thyroid dysgenesis remains
unknown. This has not been a significant issue, how-
ever, as management of CH is based on restoring thyr-
oid function to normal, not necessarily knowing the
exact underlying cause.
Epidemiology
Prior to the onset of newborn screening programs, the
incidence of congenital hypothyroidism, as diagnosed
after clinical manifestations, was in the range of 1;7,000
to 1:10,000 [1]. With the advent of screening of new-
born populations, the incidence was initially reported to
be in the range of 1:3,000 to 1:4,000 [2]. With more
experience from state, regional, and national screening
programs, it has become apparent that the incidence
varies by geographic location. A report from the French
newborn screening program summarizing a 20 year per-
iod found the incidence of permanent hypothyroidism
to be 1:10,000 [3], whereas a report from the Greek
Cypriot population over an 11 year period found the
incidence in newborns to be 1:800 [4].
A recent report showed that the incidence in the Uni-
ted States increased from 1:4,094 in 1987 to 1:2,372 in
2002 [5]. The reason(s) for the increased incidence is
not clear, but one possible explanation may be a change
in testing strategy. With increased sensitivity and accu-
racy of TSH methods, many U.S. and other programs
around the world have switched from a primary T4-fol-
low-up TSH approach to a primary TSH test. If the
TSH cutoff is lowered, more infants with milder conge-
nital hypothyroidism will be detected. In addition, there
is some variation in the incidence among different racial
and ethnic groups, and the mix of these groups has
changed. Several U.S. programs have reported a higher
incidence in the Asian, Native American, and Hispanic
populations and lower in the American Black population
as compared to the White population. A summary of
the New York State program during the years 2000 to
2003 showed some interesting demographic variations
in the incidence of congenital hypothyroidism (see
Table 1) [5]. As compared to the overall incidence of
congenital hypothyroidism, the incidence was somewhat
lower in Whites (1:1815) and Blacks (1:1902), somewhat
higher in Hispanics (1:1559), and highest in the Asian
population (1:1016). In addition, New York found the
incidence nearly double in twin births (1:876) as com-
pared to singletons (1:1765), and even higher with mul-
tiple births (1:575). Older mothers (> 39 years) had a
higher incidence (1:1,328) compared to younger mothers
(< 20 years, 1:1,703). The incidence was higher in pre-
term vs. term infants [5]. It is not clear whether that the
congenital hypothyroidism in preterm infants is transi-
ent or permanent. However, as the incidence of preterm
births has increased by approximately 20 percent over
the last 20 years, this may contribute to the reported
overall increased incidence. Nearly all screening pro-
grams report a female preponderance, approaching 2:1
female to male ratio [6]. A report from Quebec shows
this female preponderance occurs mostly with thyroid
ectopy, and less so with agenesis [7].
Clinical description
The clinical features of congenital hypothyroidism are
often subtle and many newborn infants remain undiag-
nosed at birth [8,9]. This is due in part to passage of
Table 1 Incidence of congenital hypothyroidism: Selected
demographics from New York State (2000-2003)
(modified from: Harris & Pass, Molec Genet Metab
91:268-277, 2007 [5])
Demographic Incidence
Overall 1:1681
Gender
Male 1:1763
Female 1:1601
Ethnicity
White 1:1815
Black 1:1902
Asian 1:1016
Hispanic 1:1559
Birth weight
< 1500 g 1:1396
1500 - 2500 g 1:851
> 2500 g 1:1843
Single vs. multiple births
Single 1:1765
Twin 1:876
Multiple 1:575
Mother’s age
< 20 years 1:1703
20-29 years 1:1608
30-39 years 1:1677
> 39 years 1:1328
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measured in umbilical cord serum to be 25-50 percent
of normal [10]. This provides a protective effect, espe-
cially to the fetal brain [11]. Also, the most common
form of congenital hypothyroidism has some moderately
functioning thyroid tissue [12]. The slow development
of obvious clinical symptoms [13], coupled with the
importance of early treatment led to the implementation
of widespread newborn screening for this condition [2].
However, newborn screening for hypothyroidism is not
done in many third world countries. Only an estimated
1/3 of the worldwide birth population is screened. It is
therefore important that clinicians are able to recognize
and treat the disorder.
Symptoms
Symptoms of congenital hypothyroidism are initially
nondescript; however, the maternal and pregnancy his-
tory may provide some clues. In twenty percent, gesta-
tion extends beyond forty-two weeks [8]. One may also
find evidence of maternal autoimmune thyroid disease
or an iodine deficient diet. Inadvertent radioactive
iodine treatment during pregnancy is rare. Once home,
these babies are quiet and may sleep through the night.
Additional symptoms include a hoarse cry and constipa-
tion. Neonatal hyperbilirubinemia for more than three
weeks is common. This is due to immaturity of hepatic
glucuronyl transferase [8,14]. Table 2 illustrates some
symptoms that were present at the time of diagnosis by
newborn screening. In this study, the most common
symptoms were prolonged jaundice, lethargy, feeding
difficulty and constipation [14].
Signs
Up to one third have a birth weight greater than the
ninetieth percentile [8]. On initial examination, the most
common signs are umbilical hernia, macroglossia and
cold or mottled skin [14]. Thyroid hormone is also
important in the formation and maturation of bone
[15,16].This can lead to a wide posterior fontanel of
greater than 5 mm. This, along with persistent jaundice
and poor feeding are the most striking clinical features
[12]. A few infants with congenital hypothyroidism may
h a v eap a l p a b l eg o i t e r .T h i sis usually found in thyroid
dyshormonogenesis where there is a defect in thyroid
hormone production. Pendred syndrome mentioned
below can present with deafness and a palpable goiter.
Other forms of dyshormogenesis are due to defects in
enzyme function within the thyroid gland and are dis-
cussed further in the section on etiology.
The typical appearance of a hypothyroid infant before
the advent of newborn screening is shown in the infant
in Figure 1. Features include jaundice, a puffy face and a
wide posterior fontanelle with open sutures. The nasal
bridge is flat and the eyes exhibit pseudohypertelorism.
The mouth may be slightly open revealing macroglossia.
Further examination would reveal bradycardia and a
protuberant abdomen with a large umbilical hernia.
Neurologic examination findings include hypotonia with
delayed reflexes. Skin may be cool to touch and mottled
in appearance reflecting circulatory compromise [8].
X-rays can reveal absent femoral epiphyses in up to 54%
[4]. Figure 2 shows typical radiographs of epiphyseal
dysgenesis.
Congenital malformations
Congenital hypothyroidism appears to be associated
with an increased risk of congenital malformations. In
one study of 1420 infants with congenital hypothyroid-
ism, extra thyroidal congenital malformations had a
prevalence of 8.4%. Of these, the majority were cardiac
[17]. Other associated malformations include spiky hair,
cleft palate, neurologic abnormalities and genitourinary
malformations [17-19]. Also, the incidence of congenital
hypothyroidism is increased in patients with Down’s
Syndrome [20].
Gene mutations causing congenital hypothyroidism can
be a rare cause of distinct clinical phenotypes. Most well
known is Pendred’s syndrome. Affected patients have
sensorineural deafness, hypothyroidism and goiter. This
syndrome is due to a defect in pendrin, which is a trans-
membrane chloride-iodide transporter expressed in both
the thyroid gland and the inner ear [21]. A mutation in
thyroid transcription factor 2 (TTF-2) causes a syndrome
Table 2 Prevalence of individual symptoms of
hypothyroidism at the time of diagnosis. (modified from:
Alm et al. Brit Med J 289:1171-175, 1984 [13].)
Features listed
in questionnaire
Group 1 (n = 215)
Initial T4 ≤ 30
nmol/L %
with feature
Group 2 (n = 232)
Initial T4 > 30
nmol/L %
with feature
Prolonged Jaundice 59 33**
Feeding Difficulty 35 16**
Lethargy 34 14**
Umbilical Hernia 32 18*
Macroglossia 25 12*
Constipation 18 10
Cold or mottled skin 18 10
Hypothermia 3 3
No symptoms 16 33**
Other clinical features
reported:
Abnormal cry 7 6
Edema 5 3
Hypothyroid appearance 6 2
Hypotonia 3 3
**p < 0.001, *p < 0.01.
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spiky hair also known as Bamforth-Lazarus syndrome
[22] (Figure 3). Mutations in NKX 2.1 causes congenital
hypothyroidism associated with respiratory distress and
neurologic problems such as benign hereditary chorea
and ataxia [23-25].
One clinical manifestation of long standing congenital
hypothyroidism is the Kocher-Debre- Semelaigne syn-
drome. This presents as promixal muscle weakness asso-
ciated with calf hypertrophy and resolves with thyroid
hormone treatment [26]. Other clinical syndromes that
include congenital hypothyroidism are included under
“Syndromic hypothyroidism” in Table 3.
Etiology
Permanent congenital hypothyroidism may be due to
primary or secondary (central) causes. Primary causes
include defects of thyroid gland development, deficien-
cies in thyroid hormone production, and hypothyroid-
ism resulting from defects of TSH binding or signal
transduction. Peripheral hypothyroidism results from
defects in thyroid hormone transport, metabolism, or
resistance to thyroid hormone action. Secondary or cen-
tral causes include defects of thyrotropin releasing hor-
mone (TRH) formation or binding and TSH production.
These are covered briefly in this review and are listed in
Table 3.
Transient hypothyroidism may be caused by maternal
or neonatal factors. Maternal factors include antithyroid
medications, transplacental thyrotropin receptor block-
ing antibodies and exposure to iodine deficiency or
excess. Neonatal factors include, neonatal iodine defi-
ciency or excess, congenital liver hemangiomas and
mutations in the genes encoding for DUOX and
DUOXA2 (see Table 3).
Permanent congenital hypothyroidism
In iodine sufficient countries, 85% of congenital
hypothyroidism is due to thyroid dysgenesis. This term
refers to an aberration of the embryological develop-
ment of the thyroid gland. The remaining 10-15% of
cases can be attributed to the inborn errors of thyroid
hormone synthesis, also called dyshormonogenesis, or to
defects in peripheral thyroid hormone transport, meta-
bolism, or action [27].
Thyroid dysgenesis
Thyroid dysgenesis presents in three major forms: thyr-
oid ectopy, athyreosis and thyroid hypoplasia. Thyroid
ectopy refers to an ectopic location of the thyroid gland.
Figure 1 Infant with congenital hypothyroidism. A - 3 month old infant with untreated CH; picture demonstrates hypotonic posture,
myxedematous facies, macroglossia, and umbilical hernia. B - Same infant, close up of face, showing myxedematous facies, macroglossia, and
skin mottling. C - Same infant, close up showing abdominal distension and umbilical hernia.
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the left lower extremity of two infants. The infant on the left with congenital hypothyroidism demonstrates absence of the distal femoral and
proximal tibial epiphyses, while in the normal infant on the right the distal femoral epiphysis is present.
Figure 3 Bamforth- Lazarus syndrome. An 8 month old infant with a homozygous mutation in the TTF-2 gene locus leading to congenital
hypothyroidism. Phenotypic features include, low set ears, extensive cleft palate, hypertelorism, spiky hair and low posterior hairline. (Taken from;
A novel loss-of-function mutation in TTF-2 is associated with congenital hypothyroidism, thyroid agenesis and cleft palate; Human Molecular
Genetics, 2002, Vol. 11, No. 17. Courtesy Dr. Michel Polak and the Oxford University Press.)
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1. Primary hypothyroidism
Thyroid dysgenesis: hypothyroidism due to a developmental anomaly
(Thyroid ectopia, athyreosis, hypoplasia, hemiagenesis)
Associated mutations: (these account for only 2% of thyroid dysgenesis cases; 98% unknown)
TTF-2,
NKX2.1,
NKX2.5
PAX-9
Thyroid dyshormonogenesis: hypothyroidism due to impaired hormone production
Associated mutations:
Sodium-iodide symporter defect
Thyroid peroxidase defects
Hydrogen peroxide generation defects (DUOX2, DUOXA2 gene mutations)
Pendrin defect (Pendred syndrome)
Thyroglobulin defect
Iodotyrosine deiododinase defect (DEHAL1, SECISBP2 gene mutations)
Resistance to TSH binding or signaling
Associated mutations:
TSH receptor defect
G-protein mutation: pseudohypoparathyroidism type 1a
2. Central hypothyroidism (syn: Secondary hypothyroidism)
Isolated TSH deficiency (TSH b subunit gene mutation)
Thyrotropin-releasing hormone deficiency
Isolated, pituitary stalk interruption syndrome (PSIS), hypothalamic lesion, e.g. hamartoma
Thyrotropin-releasing hormone resistance
TRH receptor gene mutation
Hypothyroidism due to deficient transcription factors involved in pituitary development or function
HESX1, LHX3, LHX4, PIT1, PROP1 gene mutations
3. Peripheral hypothyroidism
Resistance to thyroid hormone
Thyroid receptor b mutation
Abnormalities of thyroid hormone transport
Allan-Herndon-Dudley syndrome (monocarboxylase transporter 8 [MCT8] gene mutation)
4. Syndromic hypothyroidism
Pendred syndrome - (hypothyroidism- deafness - goiter) Pendrin mutation
Bamforth-Lazarus syndrome - (hypothyroidism - cleft palate - spiky hair) TTF-2 mutation
Ectodermal dysplasia - (hypohidrotic - hypothyroidism - ciliary dyskinesia)
Hypothyroidism - (dysmorphism - postaxial polydactyly - intellectual deficit)
Kocher - Deber - Semilange syndrome - (muscular pseudohypertrophy- hypothyroidism)
Benign chorea - hypothyroidism
Choreoathetosis - (hypothyroidism - neonatal respiratory distress) NKX2.1 /TTF-1 mutation
Obesity - colitis - (hypothyroidism - cardiac hypertrophy - developmental delay)
5. Transient congenital hypothyroidism
Maternal intake of antithyroid drugs
Transplacental passage of maternal TSH receptor blocking antibodies
Maternal and neonatal iodine deficiency or excess
Heterozygous mutations of THOX2 or DUOXA2
Congenital hepatic hemangioma/hemangioendothelioma
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ism due to thyroid dysgenesis and is twice as common
in females [28]. In these cases, a thyroid remnant is
usually found along the normal pathway of the thyro-
glossal duct. This represents the path taken by the
developing thyroid as it descends from the base of the
tongue to its final location in the neck [28,29]. In one
study done on hypothyroid neonates, ectopic thyroid tis-
sue was found inferior and superior to the hyoid bone,
and above the thyroid cartilage [30]. Athyreosis refers to
the complete absence of thyroid tissue. Athyreosis and
thyroid hypoplasia account for the remaining one third
of thyroid dysgenesis.
Table 4 illustrates the relative frequencies of the dif-
ferent forms of congenital hypothyroidism found in
patients screened in the Quebec newborn screening pro-
gram from 1990-2004.
Thyroid dysgenesis is generally thought to be sporadic
in occurrence. However, recent evidence points to the
possibility of a genetic component. One study of all
cases of thyroid dysgenesis found that 2% were familial
in occurrence [31]. Additional studies also showed that
7.9% of first degree relatives of infants with congenital
hypothyroidism had a thyroid developmental anomaly
[32]. There was some speculation as to a possible seaso-
nal variation in the incidence of congenital hypothyroid-
ism; however, this topic is still under debate [33,34].
Some genes have been implicated as a cause of thyroid
dysgenesis. However, these generally account for a small
number of cases [35]. These include paired box gene
eight (PAX8), TTF-2, NKX2.1 and NXK2.5 [22-25]
[36-39]. These encode for transcription factors which
are expressed both during thyroid embryogenesis and in
the normal functioning gland [29]. These transcription
factors are also expressed in other tissues of the devel-
oping fetus. Mutations in genes coding for these tran-
scription factors lead to distinct phenotypic syndromes
which are linked to their tissue expression [40]. These
are described below (see Table 5).
￿ TTF-2 - a homozygous missense mutation in TTF-
2 causes a genetic syndrome of thyroid dysgenesis,
choanal atresia, cleft palate and spiky hair [22]. This
syndrome has been recently referred to as Bamforth-
Lazarus Syndrome [35].
￿ NKX2.1 - mutations in NKX2.1,a l s ok n o w na s
TTF-1, have been associated with congenital
hypothyroidism, respiratory distress and ataxia
[23,24]. Also, recent reports describe an NKX2.1
mutation with congenital hypothyroidism and benign
chorea [25,38].
￿ NKX2.5 has been expressed in cardiac tissues; the
recent finding of NKX2.5 mutations in patients with
thyroid dysgenesis suggest a genetic cause for the
increased incidence of cardiac malformations in con-
genital hypothyroidism[39].
In contrast, PAX8 mutations seem to cause thyroid
dysgenesis in the absence of other congenital anomalies
[35-37]. However, given that PAX8 is also expressed in
the mesonephros and ureteric buds [40], this may
explain the increased incidence of genitourinary malfor-
mations in patients with congenital hypothyroidism [19].
TSH resistance
There are several forms of TSH resistance. Mutations in
the TSH receptor gene leading to thyroid hypoplasia
have been found [41]. Another form of TSH resistance
is dominantly inherited and has been linked to the long
arm of chromosome 15 [42]. Resistance occurs in the
absence of a TSH receptor mutation and can again
cause thyroid hypoplasia [43]. Pseudohypoparathyroid-
ism type 1a, caused by mutations in the alpha subunit
of the stimulatory guanine nucleotide binding protein
(Gs alpha), results in defective TSH signaling [44].
Thyroid dyshormonogenesis
Hereditary defects in virtually all the steps of thyroid hor-
mone biosynthesis and secretions have been described
and account for 10-15% of permanent congenital
hypothyroidism. These are generally transmitted in an
autosomal recessive manner, but at least one condition
has autosomal dominant inheritance. Dyshormonogen-
esis leads to goitrous hypothyroidism; however, this is
rarely seen in babies detected by newborn screening [45].
Table 4 Etiology of congenital hypothyroidism in 148
patients diagnosed in the Quebec Newborn Screening
program from 1990-2004. (modified from: Eugene et al.
J Clin Endocrinol Metab 90:2696-2700, 2005 [111])
Female Male Total Percentage
Athyreosis 14 10 24 16
Ectopic 78 24 102 68
Orthotopic/dyshormonogenesis 9 13 22 15
Totals 101 47 148 100
Table 5 Transcription factor gene mutations resulting in
thyroid dysgenesis and associated clinical findings
Mutated Gene Associated clinical findings
Thyroid transcription
factor 2 (TTF2)
thyroid dysgenesis, choanal atresia, cleft palate
and spiky hair
NKX2.1 congenital hypothyroidism, respiratory distress
ataxia and benign chorea
NKX2.5 Congenital hypothyroidism and cardiac
malformations
PAX-8 Thyroid dysgenesis, kidney and ureteral
malformations
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of thyroid peroxidase activity [46]. Thyroid peroxidase
uses hydrogen peroxide to couple iodine to thyroglobu-
lin within the thyroid gland, forming T3 and T4. Severe
defects in this enzyme lead to total iodide organification
defects (TIOD). This diagnosis is made by showing high
radioactive iodine (RAI) uptake of the thyroid gland fol-
lowed by more than 90% release after sodium perchlo-
rate administration [47] (see section on diagnosis). Less
severe mutations cause partial iodide organification
defects (PIOD). Pendred’s syndrome is a well known
form of syndromic hypothyroidism and is characterized
by a triad of hypothyroidism, goiter and deafness. This
syndrome is caused by a genetic defect in the trans-
membrane protein pendrin (encoded on 7q31), which
acts as a chloride-iodide transporter in both in the thyr-
oid gland and the inner ear. Defects in pendrin lead to
impaired iodide organification and these patients have a
positive perchlorate discharge test [21]. More recently,
mutations in the enzyme dual oxidase 2 (known as
DUOX2 or THOX2) have been found. They lead to dys-
hormonogenesis from deficient hydrogen peroxide gen-
eration and can be autosomal dominant. Their
phenotype is heterogeneous and can be permanent or
transient and cause either total or partial iodide organi-
fication defects [48]. Mutations in the dual oxidase
maturation factor (DUOXA2) gene also lead to deficient
iodide organification through similar mechanisms and
can cause partial iodide organification defects [49].
Other, rare causes of dyshormonogenesis include defects
in sodium/iodide transport, resulting from a mutation in
the gene encoding the sodium-iodide symporter [50],
and defective thyroglobulin action, resulting from a
mutation in the gene encoding thyroglobulin [51]. A
defect in the enzyme iodotyrosine deiodinase which aids
in the peripheral conversion of T4 to T3 has been
s h o w ni nh y p o t h y r o i di n d i v i d u a l s .T h i sc a nb ed u et o
homozygous mutations in the genes DEHAL1 or
SECISBP2 [52,53].
Secondary or Central hypothyroidism
Congenital secondary or central hypothyroidism gener-
ally results from defects of TSH production; most com-
monly, it is part of a disorder causing congenital
hypopituitarism. Congenital hypopituitarism often is
associated with midline defects such as septo-optic dys-
plasia or cleft lip and/or palate and can be part of a lar-
ger genetic syndrome. Mutations in genes regulating
pituitary gland development, which include HESX1,
LHX3, LHX4, PIT1 and PROP1 have been reported to
be a cause of familial hypopituitarism. Besides TSH defi-
ciency, other pituitary hormones are often deficient,
including growth hormone, adrenocorticotrophic hor-
mone and antidiuretic hormone. Rarely, specific gene
defects lead to central hypothyroidism. These include
isolated TSH deficiency (autosomal recessive, caused by
mutations in the TSH b subunit gene), and thyrotropin
releasing hormone (TRH) resistance, resulting from
mutations in the TRH receptor gene (see Table 3).
Peripheral defects in thyroid hormone
metabolism
Passage of thyroid hormone into cells is facilitated by
thyroid hormone plasma membrane transporters. A
mutation in a gene encoding monocarboxylase transpor-
ter 8 (MCT8) has been reported in five boys as a cause
of X-linked hypothyroidism associated with mental
retardation and neurologic abnormalities including
quadriplegia. The defective transporter appears to
impair the passage of T3 into neurons and is character-
ized by elevated serum T3 levels, low T4 and normal
TSH [54]. This is also known as Allan-Herndon-Dudley
syndrome.
Peripheral resistance to the action of thyroid hormone
has been described. This is due in 90% of cases to muta-
tions in genes encoding for thyroid hormone receptor b
(TR b). These mutations are dominantly inherited and
affected individuals are generally euthyroid, however
some hypothyroid individuals have been described. Cir-
culating T3 and T4 are mildly elevated without suppres-
sion of TSH. Thus these infants are usually not detected
by newborn screening [55].
Transient congenital hypothyroidism
Transient congenital hypothyroidism is found to be
more common in Europe (1:100) than the United States
(1:50,000) [3]. In a report of over twenty years in the
French newborn screening program, the incidence of
transient congenital hypothyroidism was found to be 40
percent [3]. Causes of transient congenital hypothyroid-
ism include:
￿ Iodine deficiency - Iodine deficiency is more com-
mon in European countries, especially in preterm
infants; this is due mainly to maternal iodine defi-
cient diets [3,12,56].
￿ Transfer of maternal blocking antibodies - Mater-
nal antithyroid antibodies can cross the placenta and
block the TSH receptor in the neonatal thyroid. This
effect can last up to 3 to 6 months after birth as
maternal antibody levels fall [57,58].
￿ Fetal exposure to antithyroid drugs - Maternal
antithyroid drugs can cause decreased neonatal thyr-
oid hormone synthesis which lasts for a few days to
two weeks after birth.
￿ Maternal iodine exposure - Maternally adminis-
tered amiodarone may cause transient hypothyroid-
ism in their infants. This seems to resolve at around
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adverse neurologic outcomes [59]. Transient
hypothyroidism also occurs when iodine antiseptic
compounds are used on mothers or after exposure
to iodinated contrast agents; however, this may be
related to the type and duration of exposure as a
recent study showed no abnormal thyroid functions
in the infants of 21 mothers given iodide contrast
during pregnancy [60].
￿ Neonatal Iodine exposure - Exposure of newborns
to high amounts of iodine can cause hypothyroidism.
This can occur especially in preterm infants[61].
￿ Liver hemangiomas - There are reports of congeni-
tal liver hemangiomas that produce large amounts of
the enzyme type 3 iodothyronine deiodinase. This
produces a consumptive type of hypothyroidism in
which large doses of thyroxine are required to main-
tain euthyroidism. Serum T4 levels are low, TSH is
elevated, and reverse T3 levels are also increased.
Hypothyrodism resolves as the tumor involutes or is
treated [62].
￿ Mutations in DUOX2 (THOX2)a n dDUOXA2 can
lead to transient congenital hypothyroidism as pre-
viously described [48,49].
Diagnosis
In those countries with newborn screening programs in
place, essentially all infants with congenital hypothyroid-
ism are diagnosed after detection by newborn screening
tests. Screening programs have been developed in
Canada, the United States, parts of Mexico, Western
Europe, Japan, Australia, New Zealand, and Israel, and
they are under development in parts of many countries
in Eastern Europe, Asia, South America and Africa. Of
the worldwide birth population of 127 million, it is esti-
mated that 25 percent undergo screening for congenital
hypothyroidism. In infants born in locations without
newborn screening programs, diagnosis may be made
after development of clinical manifestations of
hypothyroidism.
Newborn thyroid screening tests
The specimen used for newborn screening tests is blood
from a heel-prick collected on special filter paper cards.
The specimen is routinely collected between two and
five days of age (or at discharge from the hospital, if this
occurs earlier); some programs use cord blood for
screening. In addition, somep r o g r a m sa l s or o u t i n e l y
obtain a 2
nd specimen between two and six weeks of
age. The filter paper cards are then sent to a centralized
laboratory for testing. Early in the experience of screen-
ing, most programs undertook an initial T4 test, with a
follow-up TSH test on infants below a specified T4 cut-
off [2]. With increasing accuracy of TSH measurement,
many screening programs now carry out an initial TSH
test to detect congenital hypothyroidism. Each program
must develop its own T4 and TSH cutoff for recall of
infants with abnormal test results (see Figure 4, Diag-
nostic algorithm). As there are rapid changes in TSH
and T4 in the first few days of life, many programs have
developed age-related cutoffs. Following are examples of
typical cutoffs for T4 and TSH:
￿ Initial T4 < 10
th percentile ®follow-up TSH test
￿ Initial TSH > 30 mU/L serum (> 15 mU/L whole
blood)); some programs use an upper percentile
TSH cutoff, e.g., > 97
th percentile
Both of the above screening test approaches will
detect the majority of infants with primary congenital
hypothyroidism. There are some advantages and disad-
vantages with each approach in the detection of other
thyroid disorders. Both screening test approaches do a
good job of detecting infants with primary CH. The pri-
mary T4-follow-up TSH test strategy will detect some
infants with secondary or central (hypopituitary)
hypothyroidism and infants with “delayed TSH rise”.O n
the other hand, a primary TSH test strategy will detect
infants with mild or “subclinical” hypothyroidism (see
Table 6). Neither test approach will detect infants with
defects of thyroid transport, metabolism, or action. With
a goal of detecting all of these thyroid disorders, some
programs have undertaken pilot programs measuring
both T4 and TSH on all newborns. These programs
tend to report a higher incidence of congenital
hypothyroidism [63].
Confirmatory serum thyroid testing
Once an infant has been detected with abnormal thyroid
screening tests, they should be recalled immediately for
examination, and a venapunctue blood sample should be
obtained for confirmatory serum testing (see Figure 4,
Diagnostic algorithm). Confirmatory serum is tested for
TSH and either free T4 or total T4 combined with some
measure of binding proteins, such as a T3 resin uptake.
It is important to compare the serum results with age-
normal reference ranges. In the first few days of life,
serum TSH can be as high as 39 mU/L, as a result of
the TSH surge that occurs shortly after birth (this is the
reason that the filter paper screening test cutoff is
approximately 30 mU/L). Most confirmatory serum tests
are obtained around one to two weeks of life, when the
upper TSH range falls to approximately 10 mU/L. The
approximate normal reference ranges for serum free T4,
total T4, and TSH in the first 4 weeks of life are shown
in Table 7. Although levels of all hormones are higher
at 1-4 days of age, by 2-4 weeks of age they have fallen
closer to the levels typically seen in infancy.
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free T4 or total T4 confirms the diagnosis of primary
hypothyroidism. The finding of an elevated serum TSH
with a normal free T4 or total T4 is consistent with
subclinical primary hypothyroidism. Because of the
dependence of the developing brain on optimal concen-
trations of thyroid hormone, we recommend treating
infants with subclinical hypothyroidism.
It is now recognized that preterm infants or acutely ill
term infants with primary hypothyroidism may not
show an elevated TSH level on the 1
st screening test.
Thus, many programs undertake a routine 2
nd screen-
ing test in preterm and acutely ill term infants. Such
testing leads to the detection of infants with “delayed
TSH rise”, which occurs in approximately 1:18,000 new-
borns [64].
Figure 4 Congenital hypothyroidism: Diagnostic algorithm. Diagnostic algorithm: the diagnosis of congenital hypothyroidism begins with
either abnormal newborn screening test results or a clinical suspicion of hypothyroidism, leading to serum thyroid function tests (typically TSH
and free T4) to confirm the diagnosis. If a diagnosis of primary or secondary (central) congenital hypothyroidism is confirmed, other diagnostic
studies can be undertaken to determine the underlying etiology.
Table 6 A comparison of the thyroid disorders detected by primary T4-follow-up TSH testing vs. primary TSH testing
Disorder Primary T4-Follow-up TSH Primary TSH
Primary CH Good Good
Central CH Some No
Mild CH No Yes
Delayed rise TSH Yes No
Unusual forms of CH, e.g., defects of thyroid cell membrane transport (MCT8), metabolism or action No No
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recall infants with persistently low T4 screening levels,
e.g. on the routine 1
st and 2
nd specimens (without ele-
vated TSH levels) detect some infants with secondary or
central hypothyroidism [65]. Confirmatory serum testing
will show a low free T4 or total T4, with either a low
TSH or an “inappropriately normal” TSH level. In
infants with central hypothyroidism, the TSH deficiency
may be isolated, as in infants with TSHb gene muta-
tions. In most cases of central hypothyroidism, however,
TSH deficiency is associated with other pituitary hor-
mone deficiencies. Such infant should be investigated
for other pituitary hormone deficiencies, particularly if
they have features such as hypoglycemia, which is sug-
gestive of growth hormone (GH) and/or ACTH defi-
ciency, or micropenis and undescended testes in a male,
which are suggestive of gonadotropin (LH, FSH)
deficiencies.
Some infants who undergo serum testing because of
“low T4, non-elevated TSH” screening test results will
be discovered to have thyroxine binding globulin (TBG)
deficiency. Serum testing will show a low total T4, but a
normal free T4 and normal TSH level. TBG deficiency
can be confirmed by finding a low serum TBG level.
TBG deficiency is an X-linked recessive disorder that
occurs in approximately 1:4,000 infants, primarily males
[66]. These infants are euthyroid and treatment is not
necessary.
Diagnostic studies to determine an underlying
etiology
Treatment of congenital hypothyroidism is based on
serum thyroid function test results, as outlined above.
Other diagnostic studies may be undertaken to determine
an underlying etiology. Such diagnostic studies may
include thyroid radionuclide uptake and scan, thyroid
ultrasonography, serum thyroglobulin (Tg) measurement,
antithyroid antibody determinations, and measurement
of urinary iodine (see Table 8). Findings may guide treat-
ment decisions in infants with borderline serum test
results, e.g., discovery of a form of thyroid dysgenesis.
Results from these tests will usually separate transient
from permanent cases. If a familial form of congenital
hypothyroidism is discovered, this will guide genetic
counseling. As gene mutations have now been reported
for virtually all steps in thyroid hormone synthesis, the
above diagnostic studies may lead to a specific genetic
test to confirm the underlying etiology. In addition, these
diagnostic studies may be performed routinely in pro-
grams that use this information for clinical investigations.
However, these diagnostic studies generally do not alter
the treatment decision, and so they are considered
optional.
1. Thyroid radionuclide uptake and scan
Either iodine-123 (I-123) or sodium pertechnetate 99 m
(Tc99 m) are preferred for thyroid uptake and scan in
neonates to minimize the radioactivity exposure; I-131
delivers a higher dose to the thyroid and total body and
should not be used. Radionuclide uptake and scanning
generally are the most accurate tests in defining some
form of thyroid dysgenesis, e.g., an ectopic gland, thyr-
oid hypoplasia (decreased uptake in a eutopic location),
or thyroid aplasia [67] (Figure 5). Absence of radionu-
clide uptake should be confirmed by an ultrasonography.
Absence of uptake can also be seen with TSHb gene
mutations, TSH receptor inactivating mutations, iodide
trapping defects, and with maternal thyrotropin receptor
blocking antibodies (TRB-Ab); thyroid ultrasonography
and other studies, such as measurement of serum Tg or
TRB-Ab will help to separate these etiologies from thyr-
oid aplasia (see below).
If radionuclide studies show a large gland in a eutopic
location with increased uptake, these findings are sug-
gestive of one of the dyshormonogeneses beyond
Table 7 Reference ranges for thyroid function tests at
ages 1-4 days and 2-4 weeks [64]
Age Free T4 (pmol/L) Total T4 (nmol/L) TSH (mU/L)
1-4 days 25-64 129-283 < 39
2-4 weeks 10-26 90-206 < 10
Table 8 Findings in diagnostic studies undertaken to identify the underlying etiology of congenital hypothyroidism
Defect Radionuclide image Ultrasonography Serum thyroglobulin Maternal TRB-Ab
Aplasia No uptake Absent gland Low Negative
Hypoplasia ↓ uptake Small, eutopic Intermediate Negative
Ectopia ↓ uptake, ectopic Ectopic gland (hypoplastic) Intermediate Negative
TSHb mutations No uptake Eutopic gland (hypoplastic) Intermediate Negative
TSH receptor inactivating mutation ↓ uptake Eutopic gland Intermediate-high Negative
Trapping error ↓ or no uptake Eutopic gland Low-intermediate Negative
Beyond trapping error ↑ uptake Eutopic, large gland High Exception: Tg gene mutations Negative
Maternal TRB-Ab ↓ or no uptake Eutopic gland Low-intermediate Positive
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a perchlorate discharge test. If there is defective oxida-
tion and organification of iodide, it will not be attached
to tyrosine on thyroglobulin, and so it will be rapidly
“discharged” from the thyroid gland when high doses of
perchlorate are given. Genetic studies for a mutation in
thyroid peroxidase, the enzyme responsible for oxidation
and organification, can confirm this inborn error of
thyroid hormone biosynthesis.
2. Thyroid ultrasonography
Thyroid ultrasonography is accurate in confirming true
thyroid aplasia. In the situations described above where
radionuclide uptake and scan show absent uptake, but a
gland is actually present (TSHb gene mutations, TSH
receptor inactivating mutation, iodide trapping defect,
maternal TRB-Ab), ultrasonography may show a thyroid
gland in a eutopic location. Ultrasonography generally is
not as accurate as radionuclide scan in demonstrating
ectopic glands [68]. More recent studies report that
color flow doppler ultrasonography is able to detect
ectopic thyroid tissue in 90 percent of infants with ecto-
pic glands detected by radionuclide imaging [69]. Thyr-
oid ultrasonography can confirm a large gland,
suggestive of dyshormonogenesis.
3. Serum thyroglobulin (Tg) determination
Serum thyroglobulin levels reflect the amount of thyroid
tissue and generally are elevated with increased thyroid
activity, as when TSH is elevated. In addition, with
inflammation, more thyroglobulin “leaks” into the circu-
lation. One study showed that serum thyroglobulin
levels were lowest in neonates with thyroid aplasia
( m e a n1 2n g / m L ,r a n g e2t o5 4n g / m L ) ,i n t e r m e d i a t e
with ectopic glands (mean 92 ng/mL, range 11 to 231
ng/mL), and highest in cases associated with large
glands (mean 226 ng/mL, range 3 to 425 ng/mL) [68].
Thus, while these groups could be separated by their
serum thyroglobulin levels, given the degree of overlap
it could not be used to diagnose the etiology in indivi-
dual cases. In cases of true thyroid aplasia, serum thyro-
globulin levels are absent if measured a few weeks after
birth. Serum thyroglobulin determinations can be useful
in cases of absent radionuclide uptake. If the thyroglo-
b u l i nl e v e li si n c r e a s e d ,t h i ss u g g e s t st h a tt h et h y r o i d
gland is present, and that the neonate may have a TSH
receptor inactivating mutation [70], a trapping defect, or
maternal TRB-Ab, rather than aplasia.
4. Anti-thyroid antibodies
Maternal autoimmune thyroid disease may be associated
with production of a thryotropin receptor blocking anti-
body (TRB-Ab). This antibody will cross to the fetus
and block TSH binding, inhibiting fetal thyroid gland
development and function. Maternal autoimmune thyr-
oid disease is relatively common, as approximately 5
percent of women of reproductive age have either anti-
thyroglobulin or thyroid peroxidase antibodies [71].
However, maternal TRB-Ab is relatively rare, causing
transient congenital hypothyroidism in approxi-
mately1:100,000 neonates [57]. Thus, we only recom-
mend TRB-Ab determinati o n si nac a s ew h e r ea
previous child has had transient congenital hypothyroid-
ism, and mother has known autoimmune thyroid disease
and is pregnant again. TRB-Ab can be screened for by a
thyrotropin binding inhibitor immunoglobulin (TBII)
determination in mother.
5. Urinary iodine determination
If an infant with congenital hypothyroidism is born in
an area of endemic iodine deficiency, or if there is a his-
tory of excess iodine exposure, measurement of urinary
Figure 5 Technetium 99 m scan findings in congenital hypothyroidism. A-Technetium 99 m scan, showing a large gland (approximately
twice normal size) in eutopic location, consistent with dyshormonogenesis. B-Technetium 99 m scan, showing uptake in ectopic location, i.e.
ectopic gland. C-Minimal uptake, consistent with aplasia or severe hypoplasia.
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24 hour urinary iodine approximates iodine intake; the
normal range in neonates is approximately 50 to 100
mcg.
6. Genetic mutations
Testing for specific genetic mutations generally is only
considered after other studies point to a specific defect,
e.g, a mutation in the gene for thyroid peroxidase in a
neonate with a goiter, increased radionuclide uptake,
and positive perchlorate discharge test. As noted pre-
viously, mutations in TTF-1, NKX2.1,o rPAX-8 genes
are found in only 2% of cases of thyroid dysgenesis.
Thus, in the vast majority of cases of thyroid dysgenesis,
the underlying cause remains unknown.
Laboratories around the world offer genetic testing for
most of the following genetic disorders[72,73]:
￿ TSHb mutations
￿ TSH receptor inactivating mutations
￿ Thyroid dysgenesis
◦ TTF-2 mutations
◦ NKX2.1 mutations
◦ PAX-8 mutations
￿ Thyroid dyshormonegenesis
◦ Sodium-iodide symporter mutations
◦ Hydrogen peroxide mutations
▪ DUOX2 mutations
▪ DUOX2A mutations
◦ Thyroid peroxidase mutations
▪ Pendred syndrome (PDS): pendrin gene
mutations
◦ Thyroglobulin mutations
◦ Deiodinase mutations
￿ Defects in thyroid hormone transport
◦ MCT8 mutation
Differential diagnosis
In cases where an infant with congenital hypothyroidism
is detected by newborn screening tests and the diagnosis
is confirmed by serum thyroid function tests, a clinical
differential diagnosis is not considered. As described
under confirmatory serum thyroid testing (above),
results will lead to a diagnosis of primary congenital
hypothyroidism, subclinical hypothyroidism, and, in
some programs, secondary or central hypothyroidism.
In the absence of newborn screening programs, the
diagnosis of congenital hypothyroidism is made after
development of clinical manifestations. Since symptoms
and signs develop gradually after birth, the diagnosis of
hypothyroidism may be difficult at first. The timing of
clinical features will vary depending on the severity of
hypothyroidism. The myxedematous facial features, flat
nasal bridge, macroglossia, and hypotonia may suggest
Down syndrome or a metabolic storage disease. Pro-
longed jaundice and a protuberant abdomen may sug-
gest a congenital liver disorder such as biliary atresia.
Slow linear growth, a large head with immature body
proportions, and radiological features of epiphyseal dys-
genesis may be mistaken for a skeletal dysplasia or pitui-
tary dwarfism. Eventually the clinical symptoms and
signs suggest congenital hypothyroidism, and appropri-
ate thyroid function tests confirm the diagnosis.
Genetic counseling
The most common cause of congenital hypothyroidism,
thyroid dysgenesis, is typically a sporadic disorder, and
so there is no recurrence risk with future pregnancies.
The sporadic nature is supported by twin studies, which
show a discordance for thyroid dysgenesis in both
monozygotic and dizygotic twins [74]. There is evidence
of a familial component in some cases of thyroid dys-
genesis (aplasia, hypoplasia and ectopic glands). In a
report of 2,472 patients with congenital hypothyroidism
identified by the French newborn screening program
and shown to be a result of thyroid dysgenesis, 48 (2
percent) appeared to be familial (typically occurring in
siblings or cousins, but also some mother/father-daugh-
ter/sons) [28].Further evidence for a familial component
comes from a French study which reported that 21.4
percent of first degree relatives of patients with congeni-
tal hypothyroidism had asymptomatic thyroid develop-
mental anomalies, such as thyroglossal duct cysts,
hemiagenesis, or a pyramidal lobe, as compared to 0.9
percent in a control population [32]. This study suggests
a common genetic component between thyroid dysgen-
esis and these developmental anomalies. Rare cases of
apparent thyroid agenesis have been reported in patients
with loss-of-function mutations of the TSH receptor
[70]. These cases appear to have an autosomal recessive
pattern of inheritance. In summary, if a patient is
detected with congenital hypothyroidism and imaging
studies show some form of thyroid dysgenesis, the
families can be counseled that the recurrence risk
appears small, around 2 percent.
A minority of patients develop congenital hypothyr-
oidism as a result of a hereditary defect in thyroid hor-
mone biosynthesis, one of the dyshormonogeneses.
Dyshormonogenesis may be suspected in an infant
detected with congenital hypothyroidism and a goiter.
These inborn errors of thyroid hormone biosysnthesis
are the result of mutations in the sodium-iodide sym-
porter, thyroid peroxidase, thyroglobulin, or iodotyrosine
deiodinase genes. All of these inborn errors are autoso-
mal recessive, and so they carry a 25 percent recurrence
risk in future pregnancies. One specific disorder, Pen-
dred’s syndrome consists of sensorineural deafness, goi-
ter, and impaired iodide organification. Pendred’s
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to chromosome 7q22-33.1, and results from a mutation
in a chloride-iodide transport protein expressed in the
thyroid and inner ear [21]. While some patients with
Pendred syndrome may develop hypothyroidism at birth
[75], the majority are clinically and biochemically
euthyroid.
There is a high recurrence risk of hypothyroidism in
babies born to mothers with autoimmune thyroid disease
associated with a thyrotropin receptor blocking antibody
(TRB-Ab). Mothers should be investigated for TRB-Ab in
cases of recurrent congenital hypothyroidism in siblings.
The TRB-Ab will cross the placenta and block fetal thyr-
oid gland development. Although this is an uncommon
cause of congenital hypothyroidism [57], mothers should
be counseled that as long as they have a high concentra-
tion of TRB-Ab, future pregnancies are at risk.
Antenatal diagnosis
As congenital hypothyroidism is most commonly not a
heritable disorder, and the majority of cases are spora-
dic, it is not possible to identify a population of preg-
nant women who are at high risk for fetal
hypothyroidism. Specific pregnancies may be determined
to be at risk based on a family history of a previous
infant with congenital hypothyroidism, for example
resulting from dyshormonogenesis or maternal TRB-Ab.
Most cases, however, are not familial and are discovered
when routine ultrasonography discloses a fetal goiter
[76]. In addition, if a pregnant woman with Graves’ dis-
ease is treated with antithyroid drugs, the fetus is at risk
for hypothyroidism. Further, if a pregnant woman inad-
vertently receives radioactive iodine (RAI) after 8-10
weeks gestation, the fetal thyroid will trap the RAI,
resulting in thyroid ablation and hypothyroidism.
There are rare case reports of subsequent pregnancies
in families where a previous sibling had a familial form
of congenital hypothyroidism [77]. In cases where a
fetus is at risk for hypothyroidism, e.g., a previous infant
with congenital hypothyroidism caused by dyshormono-
genesis, or one of the rarer forms of familial thyroid
dysgenesis, or a defect in thyroid hormone transport,
where a genetic defect has been identified, genetic test-
ing on fetal cells obtained by amniocentesis will deter-
mine whether or not the current pregnancy is also
affected (for a list of defects, see 6. Genetic mutations,
under “Diagnosis”). In these recessive disorders, with a
recurrence risk of 25 percent, subsequent affected preg-
nancies may be suspected based on ultrasound findings
of a fetal goiter, along with increased amniotic fluid and
fetal bradycardia. In general, measurement of amniotic
fluid TSH or thyroid hormone levels are not reliable,
and sampling of fetal umbilical cord blood is necessary
to diagnose fetal hypothyroidism. One case discovered
by routine antenatal ultrasonography reported simulta-
neous amniotic fluid and fetal cord TSH measurements
[78]. At 32 weeks gestation, amniotic fluid TSH was
8.76 mU/L while fetal cord blood TSH was 231.00 mU/
L. With intra-amniotic injections of levothyroxine (l-
thyroxine), the amniotic fluid TSH fell to 0.95 mU/L,
while the cord blood TSH fell to 1.20 mU/L. The
authors felt in this case that the initial amniotic fluid
TSH was elevated (normal range 0.15-1.7 mU/L) and
diagnostic of fetal hypothyroidism [78]. In general,
genetic testing on fetal cells obtained by amniocentesis
is a more direct and safer method of diagnosis than fetal
cord blood sampling.
Several cases of hypothyroidism diagnosed antenatally
have undergone treatment via intra-amniotic injections
of l-thyroxine [79]. Typically, 250 mcg of l-thyroxine
(range 250 to 600 mcg) has been injected weekly into the
amniotic fluid. Subsequent dosing was based on the
treatment effect in reducing the size of the fetal goiter
and on repeat fetal cord blood thyroid tests. In general,
such antenatal monitoring and treatment is well toler-
ated, although the risks of amniotic fluid injections and
fetal cord blood sampling include premature labor, bleed-
ing, and infection. While most cases report good psycho-
motor developmental outcome, there have not been any
systematic studies of antenatal treatment of fetal
hypothyroidism. Considering that the majority of infants
with congenital hypothyroidism do well if detected by
newborn screening with treatment started within the first
2-4 weeks of life, it is unclear if antenatal treatment is
necessary for optimal neurocognitive outcome, though it
clearly is successful in shrinking fetal goiter.
The management of congenital hypothyroidism
Congenital hypothyroidism is one of the most common
treatable causes of mental retardation. Studies have
shown that the timing of therapy is crucial to neurologic
outcome. Indeed, there is an inverse relationship
between intelligence quotient (IQ) and the age at diag-
nosis [13,80]. Even when diagnosed early, neurologic
development may suffer if treatment is not optimized in
the first two to three years of life [81]. It is therefore
important for these patients to receive early treatment
and close follow up.
The overall goal of therapy is ensure that these
patients are able to have growth and mental develop-
ment that is as close as possible to their genetic poten-
tial. This is achieved by rapidly restoring the free T4
and the TSH to the normal range and then maintaining
clinical and biochemical euthyroidism.
Formulations
Levothyroxine (l-thyroxine) is the treatment of choice.
Although triiodithyronine (T3) is the biologically active
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from local deiodination of T4; thus, T3 replacement is
not needed for normal neurologic functioning. In a
study of forty seven infants given varying treatment
doses of l-thyroxine, serum T3 normalized and
remained normal regardless of the treatment dose used,
again suggesting that treatment with l-thyroxine alone is
adequate [82]. Treatment should be initiated in any
infant with a positive screening result, right after confir-
matory tests are drawn but before results are available
[82,83].
Currently, only l-thyroxine tablets are approved for
use in the United States. Thyroid suspensions prepared
by individual pharmacies may result in unreliable dos-
ing. In Europe, however, l-thyroxine drops have been
successfully used [83]. The l-thyroxine tablet should be
crushed, mixed with breast milk, formula or water and
fed to the infant. The tablet should not be mixed with
soy formula as this has been shown to interfere with
absorption. One retrospective study of 78 patients with
congenital hypothyroidism showed that infants fed soy
f o r m u l at o o ks i g n i f i c a n t l yl o n g e rt oa c h i e v eaT S H
under 10 mU/l (150 days versus 40 days) [84]. Should
the infant require soy formula, l-thyroxine should be
given halfway between feeds and thyroid function should
be monitored carefully [80]. Some nutritional supple-
ments or drugs are known to interfere with absorption
of l-thyroxine.
These include:
￿ Soy protein formulas
￿ concentrated iron
￿ calcium, aluminum hydroxide
￿ Cholestyramine and other resins
￿ fiber supplements
￿ Sucralfate
Finally, prolonged heat exposure may reduce the effi-
cacy of l-thyroxine tablets.
Dosage
The dose and timing of thyroid hormone replacement
are important in achieving optimal neurocognitive out-
come. A delay in serum T4 normalization over one
week can result in lower intelligence scores [81]. In one
study, T4 normalization beyond two weeks resulted in
patients scoring lower on behavioral and cognitive test-
ing than patients who normalized in less than two
weeks [85]. Thus, the goal of treatment should be to
restore the serum T4 to > 129 mmol/L (> 10 μg/dl) as
r a p i d l ya sp o s s i b l e .T h e r ei sa ni n v e r s er e l a t i o n s h i p
between the starting l-thyroxine dose and the time to
achieve the goal serum T4 concentration [85]. The
recommended initial l-thyro x i n ed o s es e tf o r t hb yt h e
American Academy of Pediatrics (AAP) [82] and the
European Society for Paediatric Endocrinology (ESPE) is
10-15 mcg/kg per day. In term infants this amounts to
an average of 37.5 to 50 mcg per day [86]. In the afore-
mentioned study, infants who received 50 mcg per day
(12-17 mcg/kg/day) versus 37.5 mcg (10-15 mcg/kg/day)
achieved higher performance scores for behavior, read-
ing, spelling and math. Full scale IQ scores were 11
points higher in those started on 12- 17 mcg/kg/day
[85]. Thus, for infants with low serum T4 levels, less
than 5 μg/dl we would recommend using a dose of 12-
17 mcg/kg/day, which is slightly above the higher end of
the AAP recommended dose.
Infants with severe congenital hypothyroidism are at
greater risk for developmental delay. This has been illu-
strated in studies done in both Europe, the United
States and Canada [80,85][87-89]. Therefore, rapid
replacement with adequate doses of l-thyroxine is parti-
cularly important. This point was illustrated in one
study of 83 infants who were assigned to receive three
different starting doses of thyroid hormone at birth. The
first group received 6.0-8.0 mcg/kg/day, group 2
r e c e i v e dad o s eo f8 . 1 - 1 0 . 0m c g / k g / d a ya n dG r o u p3 ,a
dose of 10.1-15.0 mcg/kg/day. These infants were then
followed for growth and intellectual outcome at four
years of age. In this study, the infants with severe conge-
nital hypothyroidism achieved the highest intellectual
scores when started at the highest dose [90]. Another
study done in 61 infants compared early versus late
treatment with low versus high dosing. Results showed
that in infants with severe congenital hypothyroidism,
only those treated early (< 13 days) and with higher
doses (>9.5 mcg/kg/day) achieved normal psychomotor
development at 10-30 months of age [81].
It is important to note that the time for TSH normali-
zation is inversely related to neurodevelopmental out-
come [86]. One study done in 45 children compared
intellectual outcome at 2 and 6 years of age with var-
iance of serum T4 and TSH. These investigators found
that scores on the mental development index (MDI) and
verbal IQ were predicted by mean T4 and TSH during
the first year of treatment [91]. Therefore it is important
to closely monitor these infants and adjust the l-thyrox-
ine dose frequently until the desired level is achieved.
Treatment Goals
The treatment goals as outlined by the American Acad-
emy of Pediatrics (AAP) Update of newborn screening
and therapy for congenital hypothyroidism [82] are simi-
lar to published European Society for Pediatric Endocri-
nology (ESPE) guidelines [86] and are as follows:
￿ Serum Free T4 or total T4 should be kept in the
upper range of normal during the first year of life.
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nmol/L (10-16 μg/dl) for the serum T4 and 18 to 30
pmol/L (1.4 to 2.3 ng/dl) for free T4.
￿ Serum TSH should be kept under 5 mU/L.
Infants who have serum T4 concentrations below 10
μg/dL in the first year of life accompanied by serum
TSH concentrations above 15 mU/L have been shown
to have lower IQ’s than infants whose serum T4 con-
centrations are above 10 μg/dL [91]. Also, higher doses
of l-thyroxine have been associated with higher intelli-
gence quotients at 7 and 8 years of life, especially in the
areas of verbal memory and verbal comprehension [92].
Thirdly, variations in serum T4 and TSH during the
first year of life have been correlated with changes in
mental development index and verbal intelligence quoti-
ent [91,93].
This would suggest that higher doses of l-thyroxine
lead to better overall developmental outcomes. However,
the last study also notes that children on high dose l-
thyroxine treatment had significant problems with
hyperactivity, delinquency and aggression [92]. Other
studies have also shown that high serum T4 levels con-
tribute to poorer attention in school aged children [94].
These highlight the dangers of overtreatment in conge-
nital hypothyroidism.
One study followed children on high dose therapy till
four years of age; this demonstrated that higher intelli-
gence quotients were observed in patients started on 10-
15 mcg/kg/day without adverse effects on growth and
skeletal maturation [90]
Recommended follow up
Clinical evaluation should be performed every few
months during the first three years of life along with fre-
quent measurements of serum T4 or free T4 and TSH.
The American Academy of Pediatrics recommends the
following monitoring schedule [86].
￿ At two and four weeks after the initiation of l-thyr-
oxine treatment
￿ Every 1-2 months during the first 6 months of life
￿ Every 3-4 months between 6 months and three
years of age
￿ Every 6-12 months thereafter until growth is
complete
￿ Four weeks after any change in dose
More frequently if results are abnormal or non-com-
pliance is suspected.
The serum T4 should normalize within one to two
weeks and the serum TSH should become normal in
most infants after one month of treatment. In some
individuals, a high TSH (10-20 mU/L) may persist
despite a normal serum T4 or vice versa [95]. In most
cases this is due to under treatment, however there are
some individuals who will have abnormal maturation of
free T4 feedback control on TSH secretion [96]. This
abnormality is thought to exist in about 10 percent of
treated individuals with congenital hypothyroidism and
may be due to resetting of the pituitary-thyroid feedback
mechanism in utero [97]. In one study of 42 patients,
the prevalence of pituitary thyroid hormone resistance
w a sa sh i g ha s4 3p e rc e n ti ny o u n g e ri n f a n t sl e s st h a n
one year and decreased to 10 percent in children and
adolescents[97]. This suggests that thyroid hormone
resistance is more common in the younger age group
and may resolve with age.
Permanent versus transient hypothyroidism
Some patients with a positive newborn screen for conge-
nital hypothyroidism have transient congenital hypothyr-
oidism. Permanent congenital hypothyroidism can be
assumed if:
￿ Ultrasonography or radionuclide imaging shows an
absent or ectopic thyroid gland, consistent with
athyreosis or thyroid dysgenesis.
￿ One can demonstrate dyshormonogenesis as dis-
cussed in the section on diagnosis.
￿ If at any time during the first year of life, the
serum TSH rises above 20 mU/L due to
undertreatment.
If permanent congenital hypothyroidism has not been
established by two to three years of age the AAP and
the ESPE recommend a 30 day trial off l-thyroxine ther-
apy [86,98].
If a low serum T4 or free T4 and an elevated TSH are
found, permanent congenital hypothyroidism is con-
firmed and the patient is restarted on therapy. If the
serum T4 or freeT4 and TSH remain normal, the pre-
sumed diagnosis is transient congenital hypothyroidism
and treatment is no longer needed. However, these
patients must be followed closely and monitored for
signs and symptoms of hypothyroidism such as consti-
pation, slowing of growth or decreased mentation. If
these appear then serum testing of thyroid function
should be performed and if inconclusive, these patients
should be continued to be followed closely with a low
threshold for re-testing. Subjects with presumed transi-
ent hypothyroidism are vulnerable to recurrence during
puberty and pregnancy and should be retested during
these times. One novel approach is the use of recombi-
nant TSH (rhTSH) to make the diagnosis of congenital
hypothyroidism without requiring withdrawal of thyroid
hormone. One study done on 10 children combined the
use of ultrasound, scintigraphy after rhTSH, and
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Page 16 of 22percholorate discharge testing. This protocol resulted in
the accurate diagnosis of permanent congenital
hypothyroidism in 8 of 10 cases without stopping thyr-
oxine. This shows that rhTSH may be of use in the
future confirmation of permanent congenital hypothyr-
oidism [99].
Prognosis
Prior to the newborn screening era, when a diagnosis of
congenital hypothyroidism was made after development
of clinical manifestations, studies reported an inverse
relationship between the age of diagnosis and IQ out-
come. A study from Pittsburgh Children’sH o s p i t a l
showed that if thyroid hormone treatment was started
between birth and 3 months of age, the mean IQ was
89 (range 64 to 107); if treatment was started between 3
and 6 months of age, the mean IQ was 71 (range 35 to
96), while if treatment did not start until after 6 months
of age, the mean IQ dropped to 54 (range 25 to 80)
[100]. A report from Sweden found that “in spite of an
efficient National Health Care Program for infants, the
diagnosis was delayed until after 3 months in 52 percent
of cases” [1].
The advent of newborn screening programs in the
mid-1970s allowed earlier detection and treatment of
infants with congenital hypothyroidism. Such efforts
have been successful in achieving a much-improved
neurocognitive outcome. Despite this, however, not all
studies report a completely normal outcome. In a recent
review of 51 published reports of IQ outcome in infants
with congenital hypothyroidism as compared to sibling
or classmate control subjects, 18 found no significant IQ
difference, while 33 found a significant difference, with
IQ ranging between 5 and 25 points lower in infants
with congenital hypothyroidism [80]. In evaluating
important variables, there is evidence that age of onset
of treatment, starting l-thyroxine treatment dose, and
severity of hypothyroidism each plays an important role
in neurocognitive outcome.
￿ Age of onset of treatment -As t u d yf r o mt h e
French National Screening Program reported the
effect of age of onset of thyroid hormone treatment,
divided into four time periods, and IQ outcome
[101]. In infants started on treatment after 30 days
of age, mean global IQ = 109.8; if started between
22 and 30 days of age, mean IQ = 107.7, between 15
and 21 days, mean IQ = 115.3, and before 15 days of
age, mean IQ = 119.2 (p=.008). Other programs,
however, have not found an effect of age of onset of
treatment. In a report from Australia, infants started
after 14 days of age had a mean full scale IQ = 98.1,
while those started before 14 days of age had a
mean IQ = 99.6 (p = NS) [102]. It should be kept in
mind that these were retrospective studies, and that
comparisons of age of onset of treatment came
about because early in the experience of screening
programs infants generally were started on treatment
at a later age, and then as screening programs
became more experienced, the age of onset of treat-
ment was lowered. A report from Italy compared
infants started before and after 21 days of age, subdi-
vided into two treatment groups: those started on
8.1-10 mcg/kg/day had a mean full scale IQ = 91 (>
21 days) vs. 96 (< 21 days). Those started on a
higher dose, 10.1-15 mcg/kg/day) had a mean IQ =
98, identical in the group before or after 21 days of
age [90]. Although these results did not reach statis-
tical significance, at the lower starting dose there
was a trend toward a better IQ with earlier treat-
ment, whereas with the higher starting dose, the IQ
in early vs. later treatment did not affect IQ out-
come. Thus, there may have been factors other than
age of onset of treatment that influenced IQ out-
come, such as initial starting dose. It does appear
that it is important to detect most cases and start
treatment by 4 weeks of age. In our review of the lit-
erature, of 11 studies comparing starting treatment
at an earlier age (12-30 days of life) vs. at a later age
(> 30 days of life), infants started at the earlier age
averaged 15.7 IQ points higher than infants started
at a later age [80].< /21>
￿ l-thyroxine starting dose - At the time newborn
screening programs were established in the mid-
1970s, the recommended starting l-thyroxine dose
was approximately 6-8 mcg/kg/day. With experience,
it became evident that higher doses were needed to
more rapidly correct the hypothyroxinemia and raise
the serum T4 into the “target range” and lower serum
TSH levels into the normal range (see Table 9). Early
Table 9 Time course of normalization of serum T4 and
TSH with initial l-thyroxine treatment dose (modified
from: LaFranchi & Austin. J Pediatr Endocrinol Metab
20:559-578, 2007[80].)
Screening
Program
l-thyroxine
dose (mcg/kg/
day)
Time to serum
T4 > 10 ug/dL
(days)
Time to serum
TSH < 9.1 mU/L
(days)
Quebec 6 45-90
Toronto 7-9 74
France 8 15 60
New
England
10 31
US (Pennsylvania) 10-14 7
150
Italy 10-15 30 30
US (Oregon) 12-17 3 14
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l-thyroxine dose of 6-8 mcg/kg/day showed a good
outcome. The New England Congenital Hypothyroid-
ism Collaborative reported a verbal IQ score of 109,
performance IQ of 107, and full scale IQ of 109 at
six years of age [103].
However, as the starting doses were increased, reach-
ing the currently recommended 10-15 mcg/kg/day, pro-
grams were able to compare IQ outcomes at various
starting l-thryoxine doses. A report from the Toronto
screening program compared psychometric outcome in
infants started on 6.4 mcg/kg/day vs. 9.0 mcg/kg/day
[92]. Verbal IQ was 98.6 vs. 106.3 (p < .01), performance
IQ was 103.8 vs. 108.2 (p = NS), and full scale IQ was
100.0 vs. 107.6 (p < .01) in the low vs. higher dose
infants, respectively. A report from Italy compared psy-
chometric outcome in infants started on three different
l-thyroxine doses: a “low” dose 6-8 mcg/kg/day, an
“intermediate” dose 8.1-10.0 mcg/kg/day, and a “high”
dose 10.1-15 mcg/kg/day [90]. The verbal IQs in the
three treatment groups were 92, 94, and 98, respectively
(p = NS); performance IQs were 85, 95, and 98, respec-
tively (p < .01), while the full scale IQs were 88, 94, and
98, respectively (p < .01). A report from the U.S. North-
west Regional Screening Program showed that infants
started on a higher l-thyroxine dose (50 mcg/day,
equivalent to 12-17 mcg/kg/day) had an IQ score 11
points higher than those started on the lower dose (37.5
mcg/day, equivalent to 9.4-12.4 mcg/kg/day) [85].
In our review of the literature, of ten studies examin-
ing the effect of different starting l-thryoxine doses on
psychometric outcome, two reported no effect, six
reported a 12.3 higher IQ with higher starting doses,
while two actually reported a 8.6 point higher IQ with
lower starting doses [80]. Overall, the preponderance of
studies found that children started on the currently
recommended l-thyroxine dose of 10-15 mcg/kg/day
appear to achieve the best IQ outcome.
￿ Severity of hypothyroidism - Infants with conge-
nital hypothyroidism have varying degrees of thyroid
hormone deficiency; the severity of hypothyroidism
likely is related to the underlying etiology (e.g, agen-
esis vs. hypoplasia/ectopia vs. dyshormonogenesis). It
is important to bear in mind, however, that the
degree of hypothyroidism is not simply related to
the size of the residual thyroid gland. Some cases of
dyshormonogenesis, with an enlarged gland, have
severe hypothyroidism. Several screening programs
have investigated psychometric outcome in relation-
ship to severity of hypothyroidism, addressing the
question of whether the most severely affected
infants may have suffered prenatal damage that is
not reversible even with early detection and treat-
ment. The screening program in England, Wales,
and Northern Ireland reported that infants with pre-
treatment serum T4 < 3.3 ug/dL had a global IQ
11.6 points lower than infants with a serum T4 > 3.3
ug/dL [104]. The Quebec Screening Network com-
pared IQ outcome in a cohort of infants with severe
hypothyroidism, as assessed by a pre-treatment T4 <
2 ug/dL and an epiphyseal surface area < .05 cm2 vs.
infants with more moderate hypothyroidism, with a
pre-treatment T4 > 2 ud/dL and an epiphyseal sur-
face area > .05 cm2 [105]. These infants were stu-
died relatively early in the experience of their
screening program, and so were started on a dose of
6 mcg/kg/day. The infants underwent serial psycho-
metric testing; at age 12 years, the cohort with
severe hypothyroidism had an IQ 16 points lower
than the moderate group (p < .007). A report from
the Northwest U.S. Regional Screening Program
reported that infants with severe hypothyroidism
(pre-treatment serum T4 < 2.2 ug/dL) had an IQ 11
points lower than a group with more moderate
hypothyroidism (p < .05) [85].
Part of the explanation for a worse psychometric out-
come in the most severely affected infants may be the
lower starting l-thyroxine doses used in the early history
of newborn screening. The Dutch newborn screening
program investigated the effect of initial starting dose (<
9 . 5o r>9 . 5m c g / k g / d a y )a n da g eo fo n s e to ft r e a t m e n t
(< 13 days or > 13 days of age) in infants judged to have
severe vs. milder hypothyroidism (pre-treatment serum
free T4 0.21 ng/dL vs. 0.67 ng/dL, respectively) [106]. In
the infants with severe hypothyroidism, psychometric
t e s t i n ga t1 0t o3 0m o n t h so fa g es h o w e dI Q2 1t o2 7
points lower in the groups treated with the lower start-
ing dose and/or later age of onset; the group started on
the higher dose and at the earlier age had the best IQ
outcome (IQ = 125). On the other hand, all of the
infants with milder hypothyroidism did well except the
group treated with the lower dose and later age of
onset, which had an IQ 22-25 points lower than the
other groups [106]. These results support the concept of
tailoring the initial starting l-thyroxine dose to the
severity of hypothyroidism [107]. When the Quebec
Screening Network used a higher starting dose, aver-
aging 11.6 mcg/kg/day, they reported that psychometric
testing did not show a difference in IQ in infants judged
to have severe vs. more moderate hypothyroidism (107
vs. 110, respectively) [108].
￿ Effect of lower serumT4 levels in the first two
years of life and non-compliance -N o r m a lb r a i n
development depends on delivery of adequate
Rastogi and LaFranchi Orphanet Journal of Rare Diseases 2010, 5:17
http://www.ojrd.com/content/5/1/17
Page 18 of 22thyroid hormone for the first two to three years of
life. Low thyroid levels during this time may result
in irreversible damage, whereas the effects of
hypothyroidism after age 3 years generally are rever-
sible when corrected. The New England Congenital
Hypothyroidism Collaborative reported that a sub-
group of 18 infants who had low serum T4 levels
(average T4 8.6 ug/dL) and low l-thyroxine dosing
(< 5 mcg/kg/day) with a history of poor compliance
i nt h ef i r s tt h r e ey e a r so fl i f e ,h a dam e a nI Qo f8 7
[109]. The larger, adequately treated group, with a
serum T4 in the target range (average T4 11.2 ug/
dL), had an IQ score of 105. This study underscored
the importance of frequent monitoring with dose
adjustments to keep serum free T4 or T4 in the tar-
get range in the first two-three years of life.
The New England Congenital Hypothyroidism Colla-
borative also found that noncompliance beyond the first
three years of life can affect cognitive performance. In a
study of 14 year old adolescents with congenital
hypothyroidism, the investigators made home visits
without forewarning. Testing showed that 44% were
inadequately treated, as judged by serum TSH > 15 mU/
L ,w i t hs e r u mT 4<6 . 6u g / d L( <8 5n m o l / L )i nt h e
majority [110]. Psychometric testing showed a mean IQ
of 106. Compliance with thyroid hormone treatment
was stressed (the dose was not changed), and one to
two years later, when thyroid testing was now improved,
repeat psychometric testing showed a mean IQ of 112
(p < .002). This study showed that noncompliance in
adolescents is common, and that improvement in com-
pliance and thyroid levels was associated with improved
cognitive function.
Unresolved questions
The underlying etiology of thyroid dysgenesis remains
largely unknown. As described in the Etiology, Epide-
miology and Genetic Counseling sections, while dys-
genesis appears sporadic, there are clues to some
familial/genetic factors. Approximately 2 percent of
cases of thyroid dysgenesis have been shown to result
from mutations in genes that code for transcription fac-
tors important in thyroid gland development, such as
TTF-2, PAX-8,a n dNKX2. The higher incidence in cer-
tain racial and ethnic groups, in preterm infants, in twin
and multiple births, and in older mothers points toward
genetic or perhaps epigenetic factors that have yet to be
discovered. In addition, the approximate 2:1 female:male
ratio overall, more apparent with ectopic glands than
with thyroid agenesis[111] is unexplained. Again, this
finding points to undiscovered genetic factors, perhaps
linked to autoimmuity, which is usually more common
in females.
The explanation for the apparent increase in incidence
of congenital hypothyroidism over the last 20 years is
unclear. Is the increase real, or is it the result of changes
in screening program test cutoffs, such that infants with
milder cases of hypothyroidism are now being detected?
Or, are there other factors, such as changes in the
racial/ethnic population mix that contribute to the
increase? It is also unclear whether the additional
infants now being detected, including those with mild
hypothyroidism and those with “delayed TSH rise” will
have permanent or transient hypothyroidism.
Management of antenatal hypothyroidism as it relates
to psychometric outcome is an open question. As dis-
cussed under Antenatal diagnosis, it is relatively rare
to discover hypothyroidism in utero. When such cases
are discovered, clinicians mayf e e lp r e s s u r et ot r e a tt h e
hypothyroidism with amniotic fluid injections of l-thyr-
oxine. However, given the good neurocognitive outcome
in infants with congenital hypothyroidism detected by
newborn screening programs and started on thyroid
hormone treatment in the first 2 to 4 weeks of life (who
are not treated in utero), and the potential risks of intra-
amniotic fluid injections and fetal cord blood sampling,
treatment after birth may be a reasonable course of
management. It is unlikely that there will ever be
enough cases to perform randomized clinical trials to
address this question. Psychometric testing in infants
both treated and not treated antenatally, however, may
provide useful information. A case can be made to treat
hypothyroidism antenatallyi fas i g n i f i c a n tg o i t e ri s
present.
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